Drug Profile
NEO 102 - NEONC Technologies
Alternative Names: NEO102 - NEONC TechnologiesLatest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator NEONC Technologies
- Class Antineoplastics; Monoterpenes; Small molecules
- Mechanism of Action Apoptosis stimulants; Ras protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Lung cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Lung-cancer in USA
- 29 Jul 2016 Early research in Lung cancer in USA (unspecified route)